ID 404558965 · FY 2018–2024 · 7 years
Georgian pharmaceutical wholesale/distribution company. Limited public information available beyond the Reportal filing.
curated 2026-06-03reportal.ge
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10,442 | 25,264 | 34,615 | 41,986 | 60,617 | 57,984 | 79,521 | +40.3% |
| Total COGS | -5,675 | -14,921 | -17,227 | -20,300 | -29,165 | -26,734 | -36,459 | +36.3% |
| Gross Profit | 4,767 | 10,342 | 17,388 | 21,686 | 31,452 | 31,250 | 43,061 | +44.3% |
| Gross Margin | 45.7% | 40.9% | 50.2% | 51.6% | 51.9% | 53.9% | 54.2% | |
| Total Operating Expenses | -2,094 | -9,078 | -10,757 | -11,852 | -12,965 | -16,031 | -18,516 | +43.8% |
| EBITDA | 2,673 | 1,264 | 6,631 | 9,834 | 18,487 | 15,219 | 24,545 | +44.7% |
| EBITDA Margin | 25.6% | 5.0% | 19.2% | 23.4% | 30.5% | 26.2% | 30.9% | |
| Total D&A | -1 | 0 | 0 | -11 | -63 | -69 | -107 | nmf |
| EBIT / Operating Income | 2,672 | 1,264 | 6,631 | 9,823 | 18,424 | 15,151 | 24,439 | +44.6% |
| Total Interest Income | 0 | 44 | 168 | 237 | 502 | 0 | 0 | nmf |
| Total Interest Expense | 0 | -4 | -27 | 0 | 0 | 0 | 0 | +519.1% |
| Total Other Income | -19 | 204 | 1,015 | -1,207 | -4,637 | 2,012 | 745 | nmf |
| Profit Before Tax | 2,653 | 1,508 | 7,787 | 8,852 | 14,288 | 17,162 | 25,184 | +45.5% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 2,653 | 1,463 | 7,787 | 10,786 | 14,288 | 17,162 | 25,184 | +45.5% |
| Net Margin | 25.4% | 5.8% | 22.5% | 25.7% | 23.6% | 29.6% | 31.7% |
Ownership & directors from companyinfo.ge (public corporate registry).